Name of this trial: Gemini-PeriOp
What type of cancer is this for? Gastroesophageal Cancer
Who is this trial for? Patients with locally advanced, resectable gastroesophageal cancer
What biomarkers are involved? Multiple cohorts include CLDN18.2, HER2 positive, and all-comers
What is the National Clinical Trial #? NCT07069712
Brief summary of this trial: Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment
Need to know: No previous treatment for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Tissue from biopsy required for central determination of mutational status.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Artemide Gastric-01
What type of cancer is this for? Gastric Cancer
Who is this trial for? Patients who have been diagnosed with gastric cancer and have not received any prior treatments.
What biomarkers are involved? HER2+
What is the National Clinical Trial #? NCT06764875
Brief summary of this trial: Randomized, Phase 3 trial of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan VS. trastuzumab, chemotherapy and pembrolizumab (standard of care arm).
Need to know: Must be HER2 positive. Tissue from previous surgery or biopsy will be sent to sponsor for confirmation of HER2 status, even if status is already known from initial testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email [email protected]